We have previously demonstrated that overexpression of HIF-1α is associated with advanced tumor stages in patients with PDAC [5, 6, 19-22] and proposed that HIF-1α is an attractive target for the development of anticancer agents [23-25]. The gene discussed is HIF1A; the disease is neoplasm.